Shares of Beigene Ltd (NASDAQ:BGNE) have been given a consensus rating of “Buy” by the fourteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $178.72.

A number of research firms recently commented on BGNE. Maxim Group set a $170.00 price target on shares of Beigene and gave the stock a “buy” rating in a research note on Monday, December 3rd. Cowen reaffirmed a “buy” rating on shares of Beigene in a research note on Sunday, October 14th. ValuEngine raised shares of Beigene from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 2nd. Piper Jaffray Companies set a $200.00 price target on shares of Beigene and gave the stock a “buy” rating in a research note on Sunday, December 2nd. Finally, BidaskClub raised shares of Beigene from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 20th.

Shares of NASDAQ:BGNE opened at $139.19 on Friday. Beigene has a 52 week low of $95.34 and a 52 week high of $220.10. The firm has a market capitalization of $8.48 billion, a price-to-earnings ratio of -63.84 and a beta of 1.70. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.57 and a quick ratio of 11.47.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($2.53) EPS for the quarter, topping analysts’ consensus estimates of ($2.97) by $0.44. Beigene had a negative net margin of 320.08% and a negative return on equity of 38.44%. The business had revenue of $54.20 million during the quarter, compared to analysts’ expectations of $47.06 million. During the same period last year, the company posted $2.54 EPS. The business’s revenue was down 75.4% on a year-over-year basis. As a group, research analysts expect that Beigene will post -10.09 EPS for the current fiscal year.

In other news, CMO Jane Huang sold 3,000 shares of the business’s stock in a transaction dated Monday, November 26th. The shares were sold at an average price of $139.58, for a total value of $418,740.00. Following the completion of the sale, the chief marketing officer now owns 271,621 shares in the company, valued at approximately $37,912,859.18. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Xiaodong Wang sold 5,000 shares of the business’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $124.30, for a total transaction of $621,500.00. Following the completion of the sale, the director now owns 3,900 shares of the company’s stock, valued at approximately $484,770. The disclosure for this sale can be found here. Insiders have sold a total of 130,122 shares of company stock valued at $17,156,904 in the last quarter. 13.30% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of BGNE. Krane Funds Advisors LLC bought a new stake in shares of Beigene in the 3rd quarter valued at about $40,000. Tower Research Capital LLC TRC raised its stake in shares of Beigene by 5,558.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 679 shares of the company’s stock worth $104,000 after acquiring an additional 667 shares in the last quarter. K.J. Harrison & Partners Inc bought a new position in shares of Beigene during the 3rd quarter worth approximately $207,000. Paloma Partners Management Co bought a new position in shares of Beigene during the 3rd quarter worth approximately $293,000. Finally, Northern Trust Corp raised its stake in shares of Beigene by 25.2% during the 2nd quarter. Northern Trust Corp now owns 2,250 shares of the company’s stock worth $346,000 after acquiring an additional 453 shares in the last quarter. Institutional investors and hedge funds own 76.70% of the company’s stock.

About Beigene

BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Featured Article: Compound Interest

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.